From trials to clinics: investigators' perspectives on translating psychedelic research into clinical care

The introduction argues that mental health treatment remains a major unmet need, with many existing psychiatric therapies ineffective for a substantial proportion of patients and few genuinely novel mechanisms entering practice in recent decades. In this context, psychedelic compounds such as MDMA and psilocybin have produced promising trial results for conditions including PTSD, addiction and treatment-resistant depression, while regulatory and political developments suggest that approval for medical use may soon be possible. However, the authors emphasise that major uncertainties remain about how treatments developed in tightly controlled trials could be incorporated into ordinary healthcare, especially given the unusual features of psychedelic care: brief but intense dosing sessions, extensive preparation and integration, and the importance of set and setting. The study set out to examine how clinical investigators, who have direct experience administering psychedelics in regulated research settings, anticipate this transition from trials to clinical care in the United States. Mitchell and colleagues aimed to understand whether investigators see psychedelic medicine as distinct from standard psychiatric treatment, what practical and ethical barriers they expect, and how they think these therapies might fit within existing healthcare systems after FDA approval.

Mitchell and colleagues used a qualitative interview study design. They identified 25 academic US psychedelic research centres through clinicaltrials.gov, scientific literature and web searches, and included centres conducting research in which psychedelics were administered to human participants as a stated focus of the programme. A key investigator from each eligible centre, usually a principal investigator or someone directly involved in administering psychedelics, was invited by email; if needed, additional investigators from the same centre were contacted. The aim was to interview one investigator per centre. In total, 31 investigators were contacted, five did not reply and five declined. The final sample comprised 21 investigators from 21 of the 25 centres. Participants were offered a $100 online gift card. The study was approved by the Baylor College of Medicine Institutional Review Board. Seventeen participants completed a demographic questionnaire, which collected descriptive information on age, gender, race, professional background and psychedelic research experience. Data collection took place between October 2024 and February 2025. Each participant completed a short Qualtrics questionnaire and then a one-to-one semi-structured interview conducted over Zoom. The interview guide was developed by a multidisciplinary team with backgrounds in social science, bioethics, psychiatry and clinical psychology. It covered four broad domains: research background, integration of psychedelics into clinical settings, use outside those settings, and equitable access. Interviews were recorded, professionally transcribed, checked for accuracy, de-identified and analysed in Dedoose. The authors used qualitative content analysis with both deductive and inductive coding. Two researchers first developed a codebook based on the interview guide and tested it on a small number of transcripts. A third researcher then inductively coded all transcripts to identify recurring ideas and themes, which were refined through group discussion and consensus among all authors. Descriptive statistics from the questionnaire were calculated in Excel. The analysis reported in the paper focused on two domains central to translation into care: perceived distinctiveness of psychedelics as medical interventions and expectations about how they would fit into current clinical structures.

The study interviewed 21 investigators from 21 centres. Of the 17 who completed the questionnaire, most were male and/or White; the mean age was 45 years, with a range from 31 to 76. Participants reported 2-33 years of psychedelic research experience and involvement in 3-20 dosing studies. Most were psychiatrists or clinical psychologists with patient-care experience. On whether psychedelics are distinct from standard psychiatric treatments, views were mixed but most participants identified several differences. Two investigators said there was very little that was unique, comparing psychedelics to other psychoactive substances. Most participants, however, described psychedelics as psychologically intense, short-term interventions that contrast with the chronic dosing typical of conventional psychopharmacology. They emphasised stronger, sometimes more durable effects, and many linked these effects to altered states and context. Several participants also highlighted reduced predictability and greater patient and therapist agency relative to standard psychotherapy. Another recurring view was that psychedelics may have broad, transdiagnostic effects, shaping not just symptom reduction but broader goals such as wellbeing, meaning, and person-centred change. Some investigators framed this as an opportunity to challenge biologically reductionist models of psychiatry, although one noted that some of the perceived uniqueness may reflect the values of the psychedelic field rather than the drugs alone. Asked about implementation, participants identified three main challenges. First, most said the role of psychotherapy or therapeutic support remained unresolved. Fifteen participants (71.4%) explicitly raised this as a major issue, and almost all (20; 95.2%) thought some form of support should accompany treatment. However, they disagreed about whether it should be mandatory and worried that regulatory or commercial pressures might minimise it. Some expected psychedelic care to resemble ketamine clinics, either in a minimal pharmacological model or in a ketamine-assisted therapy model. Participants argued that inadequate therapeutic support could lead to negative or unsafe experiences, especially given the unpredictability of psychedelic states and the possibility of psychological destabilisation. Second, cost and scalability were seen as major barriers. Fourteen participants (66.7%) raised cost explicitly. They described psychedelic treatment as resource-intensive because it often requires long dosing sessions, multiple staff, dedicated space, medical readiness for emergencies and preparation/integration visits. Some questioned how services could be billed or reimbursed, and several doubted that insurers would pay for the level of therapist time involved. At the same time, some hoped psychedelics could prompt broader changes in payer systems or in how psychiatric care is organised. Proposed ways to reduce cost included using trained non-doctorate professionals, community-based or peer models, group formats, shorter or lower-dose regimens, and other more industrialised delivery models. Third, 16 participants (76.2%) stressed that both stigma and hype shape public and professional perceptions. Stigma, rooted in drug-war attitudes, could make clinicians and patients see psychedelics as narcotics rather than medicine. Hype could create unrealistic expectations that psychedelics are a magic bullet. Participants worried that overly high hopes might lead to disappointment, shame or worsening distress if treatment did not work as expected. They also noted an ethical tension: people with the most severe and refractory conditions may be most in need of treatment, but may also be least equipped to use and integrate a psychedelic experience safely.

The authors interpret the interviews as showing that investigators see psychedelic therapies as potentially compatible with routine care, but not seamlessly so. They argue that the transition from research to clinic hinges on three linked uncertainties: how psychotherapy or therapeutic support will be incorporated, whether current treatment models can be made affordable and scalable, and how stigma and hype will affect uptake. The discussion presents these issues as central to whether psychedelic medicine can be integrated into mainstream healthcare systems rather than remaining a specialised research-based practice. Mitchell and colleagues place these findings in relation to earlier debates about whether psychedelics are exceptional within medicine. The investigators in this study generally favoured a middle position: psychedelics are distinct, but not so different that existing medical frameworks cannot be adapted. The authors suggest this can be understood as a form of epistemic humility, meaning recognition that medical knowledge is partial and may need to learn from other healing contexts. They also argue that psychedelic medicine may not only add to psychiatry’s tools but could also prompt broader reconsideration of how mental healthcare is organised. The discussion expands on the three implementation challenges. On psychotherapy, the authors note that trials vary widely and there is no consensus on the best support model, while FDA approval is unlikely to specify a single psychotherapeutic approach. This creates flexibility but also risk, because inadequate guidance could lead to poor-quality or unsafe care. On cost and scalability, they emphasise that long sessions with multiple therapists are difficult to fit into already strained mental health systems, and they highlight “misaligned incentives” as a major economic obstacle: the payer who finances treatment may not be the one who benefits later from downstream savings. They note that group models, smaller doses, shorter sessions and drug-only approaches are already being explored, but warn that cost-cutting pressures from a growing industry could compromise safety and effectiveness. On stigma and hype, the authors argue that educational efforts and rigorous trials are important but insufficient on their own. They note that research participation has been limited and that investigators are overwhelmingly White men, while racialised and gendered minorities remain underrepresented. They also point out that indigenous practices, patient experience and social science approaches are often undervalued. In their view, broadening who generates and counts as evidence is necessary to counter both stigma and hype and to improve credibility, cultural relevance and access. The authors acknowledge several limitations. The regulatory and political context is changing rapidly, so views may shift over time. The sample was limited to investigators in academic research settings in the United States and may not reflect the perspectives of patients, clinicians or researchers in other settings. Their sampling approach may not have identified every relevant centre or investigator, and demographic data were incomplete because the questionnaire was optional. As with qualitative research more generally, the findings show how participants understood these issues rather than how common those views are. Overall, the authors conclude that the differences investigators see in psychedelic medicine should not necessarily be viewed as a barrier; instead, they may offer an opportunity to improve mental healthcare, provided the clinical, economic and social uncertainties can be resolved.